ABSTRACT
INTRODUCTION
Although the pathogenesis of benign prostatic hyperplasia (BPH) is not yet completely understood, there is some evidence that prostatic inflammation could be a key contributor to prostate enlargement and progression of BPH. The presence of chronic histologic inflammation is a common finding in prostatic tissue on biopsies of surgical specimens from patients with and without lower urinary tract symptoms (LUTS) or prostatitis (1) (2) (3) . Although it is not yet defined when and why chronic inflammation occurs, it has been hypothesized that BPH is an immune-mediated inflammatory disease (2, 4, 5) . Various growth factors and cytokines including T and B lymphoid cells and macrophages have been shown to be involved in both the inflammatory process and in the interactions between epithelial and stromal prostatic cells (2) .
Several studies have investigated the relationship between histologic prostatic inflammation and LUTS related BPH (6) (7) (8) . Chronic prostate inflammatory infiltrates were at a higher risk of BPH progression and acute urinary retention when compared with patients without inflammatory infiltrates at baseline. Depending on the relationship between prostatic inflammation and LUTS, medications with anti-inflammatory effects could be a novel treatment option for the management of BPH related LUTS. We evaluated the association between prostatic inflammation and LUTS. We also characterized the effects of prostatic inflammation on the treatment of LUTS with an alpha blocker.
MATERIALS AND METhODS

Study participants
The protocol and procedures used in this study were approved by the Institutional Review Board at Ewha Medical Center. Data was retrospectively collected from 10 hospitals in Korea. Patients who met the following criteria were included in the study: (i) men, aged ≥ 50 years, (ii) total IPSS ≥ 11, (iii) maximum flow rate (MFR) < 20mL/sec. and voided volume ≥ 120mL, (iv) total prostate volume between 20 and 50g, (v) baseline serum prostate specific antigen (PSA) level between 3 and 20ng/ mL, and (vi) pathologically confirmed BPH on tissue obtained via transrectal ultrasound-guided biopsy. Exclusion criteria for this study included: (i) history of 5-alpha reductase inhibitor or alpha1--blocker use or a history of surgical therapy for BPH within 6 months of this study, (ii) neurogenic bladder, (iii) known history of an urothelial tumor such as prostate cancer or bladder cancer, and history of a urethral stricture or bladder neck obstruction, (iv) history of orthostatic hypotension with syncope, (v) history of chronic prostatitis/chronic prostatic pain syndrome, (vi) history of acute bacterial prostatitis within 6 months of this study, (vii) history of acute urinary tract infection within 1 month of this study, and (viii) history of unstable angina, myocardial infarction, or cerebro-vascular disease within 6 months of this study.
Evaluations
All data included in this study were obtained from patients who underwent transrectal ultrasound-guided biopsy of the prostate to rule out prostate cancer. All patients were treated with tamsulosin 2mg once daily for 3 months post-biopsy. Inflammation grades were reviewed by a single pathologist. The pathologist assessed the prostatic strips throughout whole specimens. Inflammation was assessed across all cores. Scoring of inflammation was based on a histologic grading system as follows: (i) grade 0, no inflammation; (ii) grade I, scattered inflammatory cell infiltrate without nodules; (iii) grade II, no confluent lymphoid nodules; (iv) grade III, large inflammatory areas with confluence (9) . We assessed all specimens for degree of inflammation according to the most frequent and most severe scores.
The primary endpoint was the difference in total IPSS according to the prostatic inflammation grade. Secondary endpoints were the differences in IPSS subscales and quality of life scores with respect to prostatic inflammation grade. Baseline LUTS parameters including uroflowmetry data, IPSS, PSA, and prostate volume were evaluated for an association with prostatic inflammation. Uroflowmetry data included voided volume, maximum flow rate, average flow rate, and post-void residual urine (PVR) volume. IPSS was evaluated using a total index score (items 1-7), storage subscale (items 2,4,7), voiding subscale (items 1, 3, 5, 6) , and a quality of life item. Total and transitional zone prostate volumes and serum PSA levels were analyzed according to the prostatic inflammation grade. The effect of alpha blocker therapy for LUTS was evaluated according to the inflammation grade. The changes in total IPSS and subscales in the storage and voiding domains, quality of life (QoL) index, MFR, AFR, and post-void residual urine volume were measured at baseline and at 3 months. Improvement was defined as an increase in maximum flow rate > 3m/s or > 25% improvement in total IPSS. Safety parameters monitored included changes in systolic and diastolic blood pressures, and serious adverse events were recorded.
Statistical analysis
We assessed differences in clinical parameters such as MFR, average flow rate (AFR), PVR, IPSS, prostate volume, and PSA level using paired t-tests or Wilcoxon signed-rank tests with Bonferroni correction. We analyzed differences in clinical parameters according to the inflammation grade using Kruskal-Wallis tests and Wilcoxon rank-sum tests with Bonferroni adjustment. All analyses were performed using SAS software version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Participants
A total of 111 patients from 10 hospitals were included in this study. Inflammation grades were assigned based on the most frequent score, with 25 patients at grade 0, 60 at grade I, and 26 at grade II. The mean age of each group was 64.3 (grade 0), 65.6 (grade I), and 64.9 years (grade II). The duration of treatment for each group was 6.9, 5.6, and 4.5 months (grades 0, I, and II, respectively). There were no significant differences in demographic data between the groups (Table-1) .
Baseline LUTS parameters and prostatic inflammation grades
Differences in baseline LUTS parameters according to inflammation grade were evaluated. The mean MFR of each group was 13.5 (grade 0), 11.9 (grade I), and 10 (grade II). The mean AFR of each group was 8 (grade 0), 6.2 (grade I), and 5.1 (grade II). Lower grade inflammation was associated with higher MFR and AFR (p < 0.05). Mean total prostate volume in each group was 36.3 (grade 0), 38.9 Table 1 (grade I), and 47.9 (grade II). Higher grade inflammation was associated with larger prostate volumes including total and transitional zone volumes (p < 0.05). Baseline IPSS and QoL scores were unrelated to prostatic inflammation grade. In terms of serum PSA, patients with higher inflammation grades had significantly higher PSA levels (p < 0.05) ( Table-2) .
-Demographic data of study participants (mean [SD], median [IQR]).
Alpha blocker treatment effects according to inflammation grade
We evaluated changes in clinical parameters and symptom scores according to inflammation grade after 3 months of treatment with an alpha blocker (Table-3 ). Voided volume, MFR, AFR, and PVR improved after 3 months of alpha blocker therapy, although these changes were unrelated to inflammation grade (p > 0.05). Similarly, IPSS improved after alpha blocker treatment, independent of inflammation grade.
The association between inflammation grade and symptomatic improvement
We evaluated whether or not improvement of LUTS was related to inflammation grade. According to the most popular inflammation scoring system, 80% of patients with grade 0 prostatic inflammation experienced improvement in their LUTS. Seventy-three percent and 92.3% of patients with grade I and grade II inflammation, respectively, had improvement of LUTS. There was no significant difference in improvement rates among the three groups (p = 0.1363). According to the most stringent inflammation scoring system, 82% of patients who had grade 0 inflammation experienced improvement. Additionally, 72%, 83.7%, and 100% of patients with grade I, II, and III inflammation, respectively, had improvement of LUTS (p = 0.3185) ( Table-4) .
Predictive factors for treatment responses to alpha blockers
Factors that predicted symptomatic improvement as a result of alpha blocker therapy were evaluated using univariate and multivariate analysis. Longer duration of medication use was related to decreased symptomatic improvement (OR = 0.92, 95% CI 0.85 -0.99). Increased IPSS voiding subscales were associated with an increase in symptomatic improvement (OR = 1.17, 95% CI 1.02 -1.34). Thus, more severe symptoms, which were represented by high IPSS voiding scores, could be predictive of improvement of LUTS with alpha blocker therapy (Tables 5 and 6 ).
Safety
Systolic blood pressures were decreased by a mean of 4.3mmHg after 3 months of treatment with an alpha blocker compared to baseline, while diastolic blood pressures were decreased by a mean of 4.7mmHg. There were no serious adverse events related to treatment with tamsulosin.
DISCUSSION
The present study sought to evaluate whether there is a correlation between histologically graded prostatic inflammation and prostate-related lower urinary tract symptoms. Our data suggest that prostatic inflammation grades are associated with LUTS, and that high grade inflammation was associated with lower urine flow rates and higher prostate volumes than low grade inflammation.
Prostatic inflammation is gaining increasing attention as a potential etiologic factor in prostate cancer, benign prostatic hyperplasia, lower urinary tract symptoms, and chronic pelvic pain syndrome (CPPS). In a mouse model, acute bacterial inflammation of the prostate was associated with epithelial proliferation and reactive hyperplasia (10) . This study concluded that transurethral inoculation of uropathogenic E.coli 1677 reliably infected the mouse prostate, produced a significant inflammatory response, and induced quantifiable epithelial proliferation and reactive hyperplasia.
Similar to the intestine and the lung, the prostate is considered to be an immune-competent organ. It is populated by a small number of inflammatory cells (leukocytes) that increase with age and consist of scattered stromal and intraepithelial T and B lymphocytes, macrophages, and mast cells. Several reports have evaluated the constituents of inflammatory infiltrates in patients with BPH. The REDUCE study reported that chronic inflammation is observed in 77.6% of patients with LUTS, and that the higher the average chronic inflammation score, the higher the IPSS. In the (11) . Additionally, inflammation detected on prostate biopsies performed during a baseline assessment in a subgroup of over 1000 patients enrolled in the MTOPS study predicted progression including symptom worsening, acute urinary retention, and the need for operative management in placebo--treated patients (12) . Basic and clinical research have sought to better elucidate the prostatic inflammation pathways and their relationship with BPH and prostate cancer, with a goal of identifying new therapeutic targets and strategies for reducing the risk of benign and malignant tumors of the prostate (13) . Nickel raised the possibility of using anti--inflammatory agents as an additional treatment option for patients with BPH (6). Several reports have suggested that combination therapy of an alpha-blocker and an anti-inflammatory agent was more effective for treatment of BPH than monotherapy with an alpha blocker (14) (15) (16) . Therefore, the management of intraprostatic inflammation plays an important role in the improvement of IPSS in patients with prostatic hyperplasia (17) .
In this study, we found that lower grade inflammation was associated with higher MFR and AFR, and higher grade inflammation was related to larger prostate volume including total and transitional zone volume. As a result, higher grade inflammation may lead to increased prostate volume and subsequent increased severity of LUTS. However, caution must be taken in interpreting these results, as prostate volume itself had an association with LUTS. While greater prostate volume was associated with more severe LUTS, prostatic inflammation may also be an effect of the symptoms themselves, though it is difficult to distinguish direct and indirect causes of dysfunctional voiding. Furthermore, baseline IPSS and QoL scores were unrelated to prostatic inflammation grade. Similarly, Nickel et al. previously reported that higher average chronic inflammation scores were associated with higher IPSS, though there were no differences in IPSS or QoL scores prior to treatment among the three groups (8) . Thus, subjective symptoms at baseline may not be associated with the degree of prostatic inflammation.
Regarding factors that were predictive of alpha blocker treatment outcomes, more severe symptoms and shorter duration of treatment predicted improvement of symptoms. This is likely because symptom severity may not be directly related to the duration of treatment. We were unable to demonstrate a relationship between improvement of symptoms after alpha blocker treatment and inflammation grade.
This study was inherently limited by its retrospective design, though data were collected from 10 different hospitals to decrease the risk of bias. We included patients with PSA levels of 3-20ng/mL and excluded one patient who was found to have prostate cancer on tissue biopsy. These inclusion criteria reflect those of a previous study by Kryvenko et al. That group analyzed the association between prostatic inflammation and pre-neoplastic lesions as risk factors for prostate cancer (18) . They concluded that clinicians should consider patterns and extent of inflammation when managing high-risk patients with negative biopsy results. Therefore, the evaluation of pattern and extent of inflammation in prostate tissue has emerged as an important factor influencing treatment. Further studies will be required to confirm and extend these collective results.
CONCLUSIONS
Patients with high grade inflammation had lower urine flow rates and higher prostate volumes than patients with low grade inflammation. Prostatic inflammation grade did not affect outcomes of alpha blocker treatment. More severe symptoms, which were represented by high IPSS voiding scores, could be predictive of improvement of LUTS after treatment with an alpha blocker. Further studies will be required to investigate the causally related link between these findings.
